The Typhoid Vaccine Acceleration Consortium (TyVAC) has identified Nigeria as a priority country for the introduction of new typhoid conjugate vaccines (TCVs) in order to reduce the burden of typhoid. As a member of TyVAC, PATH is focused on providing new evidence related to typhoid disease burden, antimicrobial resistance, cost-effectiveness, health impact analyses, and data to support the introduction of TCV in Nigeria.

To achieve this goal, PATH has engaged the Solina Centre for International Development and Research (SCIDaR) to collate data and evidence for the advocacy and engagement of decision-makers in Nigeria.

The four main objectives of this collaboration include mapping stakeholders involved in the new vaccine introduction (NVI) in Nigeria, mapping the typhoid data landscape in Nigeria, collating available evidence on typhoid disease burden, and co-developing a national stakeholder forum on typhoid. Despite early efforts, further action is needed to facilitate the introduction of TCV for vulnerable populations in Nigeria.